Kazakhstan Pharmaceuticals & Healthcare Report Q1 2008
Business Monitor International, February 2008, Pages: 51
The Kazakhstan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Kazakhstans pharmaceuticals and healthcare industry.
The pharmaceutical market in Kazakhstan is one of the most dynamic in Central Asia, typified by increasing numbers of foreign entrants. The country, being the second largest (after Russia) of the former Soviet republics, offers considerable commercial opportunities to foreign pharmaceutical players. Kazakhstan also boasts the most secure and stable political environment in the region, which has propelled its economic growth since the independence in 1991.
Kazakhstans drug sales have also posted a strong growth in recent years, largely on the back of high oil revenues. Moreover, the government is planning to raise health spending to 4% of GDP by 2010, with some US$1.3bn set to be invested. In Q107, the country’s pharmaceutical market grew by over 23% in relation to the same period in 2006. The author is predicting annual growth of between 15% and 20% over the coming years, above the overall economic growth levels. The grey market of products from Russia and
Ukraine and a black market in unregistered products accounts for an additional 10% of the market, which is not reflected in our forecasts. With growing consumer health awareness and desire to avoid run down health facilities, the over-the-counter (OTC) market - which accounts for around one-quarter of total value - will grow at a strong pace.
In the the revised Business Environment Ranking matrix for Central and Eastern Europe (CEE), Kazakhstan is ranked joint fourteenth, alongside Ukraine, out of the 16 regional markets surveyed. While enjoying a considerable level of political and economic stability, the country is marked down for absolute market value and per capita consumption of medicines, as well as the lack of universal reimbursement.
The pharmaceutical market is largely reliant on imports. Leading players on the local pharmaceutical market include foreign companies Sanofi-Aventis (France), Hungarys Gedeon Richter, Swiss Nycomed and Berlin Chemie-Menarini. Chimpharm is the key domestic producer of pharmaceuticals, accounting for over half of total local output. However, its presence in other markets is limited. In more recent years, Asian generic companies (including Indian and Malaysian producers) have made more of an impact on the Kazakhstan’s pharmaceutical marketplace, with the trend likely to continue over the forecast period.
Executive Summary 5
Kazakhstan Pharmaceuticals And Healthcare SWOT 6
Kazakhstan Political SWOT 7
Kazakhstan Economic SWOT 8
Business Environment Rating 9
Pharmaceutical Ratings - Revised Methodology 9
Ratings Overview 9
Table: Pharmaceutical Business Environment Indicators 10
Weighting 11
Table: Weighting Of Components 11
Kazakhstan - Business Environment Ranking 12
Table: Pharmaceutical Business Environment Rankings 12
Limits Of Potential Returns 12
Risks To Realisation Of Returns 13
Kazakhstan - Market Summary 14
Regulatory Regime15
Intellectual Property Environment 16
Counterfeit Drugs 16
Pricing And Reimbursement Regime 16
Table: Price Components And Add-ons For Imported And Locally Produced Generic Medicines (KZT) 17
Industry Developments18
Health Status 18
Healthcare Sector 18
Healthcare Sector Financing 19
Domestic Pharmaceutical Industry 19
Wholesale And Retail 20
Recent Domestic Industry Developments 20
Foreign Pharmaceutical Industry 21
Table: Indo-Kazakh Trade Figures (US$mn) 21
Recent Foreign Industry Developments 22
Table: Pharmaniaga Key Products 23
Industry Forecast Scenario 25
Overall Market Forecast 25
Table: Kazakhstan - Drug Market Indicators 26
Key Growth Factors - Industry 27
Table: Kazakhstan Health Expenditure Forecast Indicators 27
Key Growth Factors - Macroeconomic 28
Table: Kazakhstan - Economic Activity 29
Prescription Market Forecast 30
Table: Kazakhstan’s Prescription Drug Market Indicators (US$’000 unless otherwise stated) 31
OTC Market Forecast 32
Table: Kazakhstan OTC Market Forecast Indicators (US$’000 unless otherwise stated) 32
Generics And Patented Market Forecast 33
Table: Kazakhstan’s Generics And Branded Market Forecast Indicators 34
Export/Import Market Forecasts 35
Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006 36
Table: Trade Figures (US$mn) 36
Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006 37
Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006 38
Other Healthcare Data Forecasts 39
Table: Other Healthcare Data 39
Key Risks To our Forecast Scenario 39
Competitive Landscape40
Table: Top 10 Manufacturers By Value Of Hospital Purchases 40
Table: Top 10 Manufacturers By Retail Pharmacy Sales 41
Table: Top 10 Trade Names By Value Of Hospital Purcha 41
Table: Top 10 INNs By Value Of Hospital Purchases 42
Table: Top 10 INNs by Retail Pharmacy Sales 42
Table: Top 10 ATC Groups By Value Of Hospital Purchas 43
Table: Top 10 ATC Groups By Retail Pharmacy Sales 43
Company Monitor44
Foreign Companies 44
Nycomed 44
Ranbaxy 45
Indigenous Companies 46
Chimpharm 46
Romat FK 47
BMI Forecast Modelling49
How We Generate Our Industry Forecasts 49
Pharmaceutical Industry 50
Sources 50
- Chimpharm
- Nycomed
- Ranbaxy
- Romat FK
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
